Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986158 + nivolumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**BMS-986158 + nivolumab** is a **combination therapy** investigated in clinical trials for advanced solid tumors and hematologic malignancies[1][2][5][7]. BMS-986158 is a small molecule inhibitor of the bromodomain and extra-terminal (BET) proteins (especially BRD2, BRD3, BRD4), acting as an epigenetic modulator that disrupts transcription of cancer-promoting genes such as MYC[3][9]. Nivolumab is a monoclonal antibody targeting the programmed death-1 (PD-1) receptor, functioning as a checkpoint inhibitor to enhance anti-tumor immune response[1][6]. The rationale for the combination is to pair BET inhibition’s anti-proliferative and transcriptional regulatory effects with nivolumab’s immunotherapy, potentially improving outcomes in cancers resistant to monotherapy[1][5].
- Brand names
- Opdivo
- Other names
- BET inhibitor + nivolumabBMS-986158 + Opdivo
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)BRD4 (Bromodomain-containing protein 4)BRD2 (Bromodomain-containing protein 2)BRD3 (Bromodomain-containing protein 3)
Beyond the preview
Go deeper on BMS-986158 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986158 + nivolumab.